Clinical Trials Directory

Trials / Unknown

UnknownNCT02789592

Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease

A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
30 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether melatonin prolonged-release (PR) and clonazepam are effective and safe in the treatment of rapid eye movement behavior disorder (RBD) of patients with Parkinson's disease (PD).

Detailed description

RBD is one of the representative non-motor symptoms of PD. Patients with RBD show dream-enacting behaviors such as punching, kicking, singing, screaming, or somnambulism. These can interfere in sleep quality and increase the risk of falling down from the bed and physical injuries of both the patient and sleep partner. Therefore, qualities of life of the patient and sleep partner are negatively influenced by presence of RBD. Clonazepam has been used for treatment of choice of RBD. However, the efficacy of clonazepam is not proven in the clinical trial. Clonazepam has several side effects that could be problematic in PD patients such as increasing fall-down risk, daytime somnolence, and cognitive decline. Melatonin is a second-line treatment option for RBD, but there has been only one randomized crossover trial that evaluated the efficacy of melatonin on RBD. Finally, there has been no study that evaluate and compare the efficacy and safety of melatonin and clonazepam for treatment of RBD.

Conditions

Interventions

TypeNameDescription
DRUGMelatonin PRFor experimental treatment of RBD
DRUGClonazepamFor experimental treatment of RBD
DRUGMelatonin PR placeboPlacebo pill manufactured to mask melatonin PR 2mg tablet
DRUGClonazepam placeboPlacebo pill manufactured to mask clonazepam 0.5mg tablet

Timeline

Start date
2016-07-01
Primary completion
2019-12-01
Completion
2019-12-01
First posted
2016-06-03
Last updated
2016-06-03

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02789592. Inclusion in this directory is not an endorsement.